











100% Technical Success (Insertion and Drug Delivery) & Absence of Major Adverse Events at 30d								
• 46 patients treated at 6 OUS sites (Australia, Colombia (2), Hong Kong, Latvia, & New Zealand)								
The study met primary outcomes iafety at 30 days:	i	Late Outcomes (>30 days):						
Relevant Events	n (%)	Event	n (%)					
Transient elevation of LFTs (Asymptomatic, resolved by 30 Days)	4/46 (8.7%)	Death (1= COVID19 @256d, 1=pneumonia @38d)	2/46 (4.3%)					
Elevated Renal Function (Two resolved by 30 days; one not evaluated)	3/46 (6.5%)							
Atheromatous Embolization (Conservative management, resolved 24 hrs)	1/46 (2.2%)							
Access Site Complication	4/46 (8.7%)							

		Baseline	6-mos	12 mos	24 mos	36 mos
>42.5 mm	Annual 2.5 mm Δmm (n)	46.2 (24)	+0.2 (23)	+1.1 (21)	+1.3 (12)	+1.0 (3)
	Annual %	0.0%	0.5 %	2.4%	2.9%	2.2 %
35−42.5mm Δmr	Annual ∆mm (n)	38.7 (21)	+0.3 (21)	+0.7 (16)	+1.2 (5)	-
	Annual %	0.0%	0.6%	1.7%	3.1%	-
Patients Enrolled dated Oct 16, 2024		n = 45	n = 44	n = 37	n = 17	n = 3

		Baseline	6-mos	12 mos	24 mos	36 mos
>42.5 mm		75.6 (24)	+2.6 (23)	+7.5 (21)	+8.6 (12)	+5.9 (3)
	Annual %	0.0%	3.2 %	9.8%	11.9 %	7.6 %
35 – 42.5mm	Annual Δcc (n)	53.2 (21)	+1.9 (21)	+3.6 (16)	5.0 (5)	-
	Annual %	0.0%	3.5%	7.1%	12.1%	-
6 Patients Enrolled Ipdoted Oct 16, 2024		n = 45	n = 44	n = 37	n = 17	n = 3









